Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache

NCT04845178 is registered in ClinicalTrials.gov with AEON Biopharma, Inc. as lead sponsor.

NCT NCT04845178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04845178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Lead sponsor
AEON Biopharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2021
Completion date
August 6, 2024
Enrollment
797 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

migraine